COMMUNIQUÉS West-GlobeNewswire

Helsinn: First Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Dr Sarah A Buckley

06/06/2017 - 10:30

First Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Dr. Sarah A. Buckley, MD, University of Washington Lugano, Switzerland, [...]

Ortho Clinical Diagnostics VITROS(R) NephroCheck(R) Test for Prediction of Acute Kidney Injury Cleared, Available in Europe

06/06/2017 - 08:30

New test expands Ortho's VITROS(R) menu RARITAN, NJ--(Marketwired - Jun 6, 2017) - Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced the launch of its VITROS® NephroCheck® test, the [...]

Basilea announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553 at ASCO meeting

06/06/2017 - 07:15

Basel, Switzerland, June 6, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that updates were presented on the ongoing clinical phase 1/2a program with its anticancer drug candidate BAL101553, a novel [...]

Novartis drug Tasigna receives EU approval for inclusion of Treatment-free Remission (TFR) data in product label

06/06/2017 - 07:15

Tasigna is the first and only tyrosine kinase inhibitor (TKI) to include information on stopping therapy in Ph+ CML-CP patients in the EU product information Approval based on Novartis trials evaluating TFR with Tasigna [...]

Targovax presents further positive clinical data from TG01 phase I/II trial at 2017 ASCO annual meeting

06/06/2017 - 07:01

Oslo, Norway, 6 June 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resistant solid tumors, today announces that [...]

VALNEVA Présentera à la Conférence Global Healthcare 2017 de Jefferies à New York

06/06/2017 - 07:00

Valneva Présentera à la Conférence Global Healthcare 2017 de Jefferies à New York Lyon (France), 6 juin 2017 - Valneva SE ("Valneva" ou "le Groupe"), société de biotechnologie dédiée au développement, à la production et [...]

VALNEVA to Present at Jefferies 2017 Global Healthcare Conference in New York

06/06/2017 - 07:00

Valneva to Present at Jefferies 2017 Global Healthcare Conference in New York Lyon (France), June 06, 2017 - Valneva SE ("Valneva" or "the Company"), a fully integrated, commercial stage biotech company focused on [...]

Targovax announces formal agenda for 2017 Capital Markets Updates in Oslo and London

06/06/2017 - 07:00

Oslo, Norway, 6 June 2017 - Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces formal agenda for its Capital [...]

Addex Annual General Meeting Scheduled for 22 June 2017

06/06/2017 - 07:00

Geneva, Switzerland 6 June 2017 - Addex Therapeutics (SIX: ADXN), announced today that its Annual General Meeting will take place on Thursday, 22 June 2017, at 11:00am at the Campus Biotech, Chemin des Mines 9, 1202 [...]

Michael Phelps, athlète champion du monde et défenseur de la santé mentale, nommé au Conseil d'administration de Medibio

06/06/2017 - 06:34

SYDNEY, Australie, le 6 juin 2017 (GLOBE NEWSWIRE) - Medibio Limited (ASX : MEB) (MEB ou la Société), société de technologie médicale cotée sur ASX qui a développé un test objectif efficace pour aider au diagnostic de [...]

Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer

05/06/2017 - 22:05

Phase I/II study to evaluate Mekinist ® (trametinib) in combination with Opdivo ® (nivolumab) and Opdivo + Yervoy ® (ipilimumab) Collaboration expands upon existing clinical investigation of Opdivo combination with [...]

NANOBIOTIX : données prometteuses de l'essai de phase I/II dans les cancers de la Tête et du Cou avec NBTXR3 ; présentées au Congres Annuel de L'ASCO

05/06/2017 - 18:00

NANOBIOTIX : DONNEES PROMETTEUSES DE l'ESSAI DE PHASE I/II DANS LES CANCERS DE LA TETE ET DU COU AVEC NBTXR3 ; PRESENTEES AU CONGRES ANNUEL DE L'ASCO Très bon profil de sécurité sans aucun effet indésirable chez des [...]

NANOBIOTIX : promising data from phase I/II Head and Neck cancer trial with NBTXR3 presented at the American Society of Clinical Oncology's Annual Meeting

05/06/2017 - 18:00

NANOBIOTIX: PROMISING DATA FROM PHASE I/II HEAD AND NECK CANCER TRIAL WITH NBTXR3 PRESENTED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY'S ANNUAL MEETING Very good safety profile with no AEs and SAEs in stage III/IV in [...]

Bio-on presents a revolutionary new technology to eliminate oil pollution in the sea within 3 weeks

05/06/2017 - 15:09

Bio-on presents a revolutionary new technology to eliminate oil pollution in the sea within 3 weeks. New Minerv Biorecovery technology, patented worldwide by Bio-on and based on the revolutionary 100% biodegradable [...]

Bio-on présente une nouvelle technologie révolutionnaire pour éliminer en 3 semaines la pollution marine par le pétrole

05/06/2017 - 15:09

Bio-on présente une nouvelle technologie révolutionnaire pour éliminer en 3 semaines la pollution marine par le pétrole. La nouvelle technologie Minerv Biorecovery, brevetée par Bio-on dans le monde entier et s'appuyant [...]

HalioDx : Immunosign® gene signature assesses LTX-315 ability to turn 'cold' tumors 'hot' at ASCO 2017

05/06/2017 - 15:00

Immunosign® gene signature assesses LTX-315 ability to turn 'cold' tumors 'hot' at ASCO 2017 Immune gene expression signature Immmunosign® was applied to a set of pre and post LTX-315 treatment biopsies Immunosign® [...]

HalioDx : HalioDx highlights use of Immunosign® to define CAR T-cell therapy signature in tumor at ASCO 2017

05/06/2017 - 15:00

HalioDx highlights use of Immunosign® to define CAR T-cell therapy signature in tumor at ASCO 2017 For the first time, a tumor microenvironment immune gene signature associated with CAR T-cell treatment of non-Hodgkin [...]

Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

05/06/2017 - 15:00

Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia Analysis shows statistically [...]

Silmäasema Oyj's public offering has been oversubscribed and the subscription period discontinued

05/06/2017 - 15:00

Stock Exchange Release 5 June 2017, at 4 p.m. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, SOUTH AFRICA, SINGAPORE OR JAPAN OR ANY [...]